BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2810123)

  • 1. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats.
    van Hoogdalem EJ; Heijligers-Feijen CD; Mathôt RA; Wackwitz AT; van Bree JB; Verhoef JC; de Boer AG; Breimer DD
    J Pharmacol Exp Ther; 1989 Nov; 251(2):741-4. PubMed ID: 2810123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption enhancement of rectally infused insulin by sodium tauro-24,25-dihydrofusidate (STDHF) in rats.
    van Hoogdalem EJ; Heijligers-Feijen CD; Verhoef JC; de Boer AG; Breimer DD
    Pharm Res; 1990 Feb; 7(2):180-3. PubMed ID: 2106676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of sodium tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models.
    Baldwin PA; Klingbeil CK; Grimm CJ; Longenecker JP
    Pharm Res; 1990 May; 7(5):547-52. PubMed ID: 2367323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical effects of absorption enhancing agents on the rectal mucosa of rats in vivo.
    van Hoogdalem EJ; Vermeij-Kerrs C; de Boer AG; Breimer DD
    J Pharm Sci; 1990 Oct; 79(10):866-70. PubMed ID: 2280353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Amino-1-hydroxypropylidene-1,1-diphosphonate (APD): a novel enhancer of rectal cefoxitin absorption in rats.
    van Hoogdalem EJ; Wackwitz AT; de Boer AG; Breimer DD
    J Pharm Pharmacol; 1989 May; 41(5):339-41. PubMed ID: 2569522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects.
    Kissel T; Drewe J; Bantle S; Rummelt A; Beglinger C
    Pharm Res; 1992 Jan; 9(1):52-7. PubMed ID: 1589410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy.
    Hurni MA; Noach AB; Blom-Roosemalen MC; de Boer AG; Nagelkerke JF; Breimer DD
    J Pharmacol Exp Ther; 1993 Nov; 267(2):942-50. PubMed ID: 7504101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption enhancement of intranasally administered insulin by sodium taurodihydrofusidate (STDHF) in rabbits and rats.
    Deurloo MJ; Hermens WA; Romeyn SG; Verhoef JC; Merkus FW
    Pharm Res; 1989 Oct; 6(10):853-6. PubMed ID: 2692018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate-controlled rectal absorption enhancement of cefoxitin by co-administration of sodium salicylate or sodium octanoate in healthy volunteers.
    Van Hoogdalem EJ; Wackwitz AT; De Boer AG; Cohen AF; Breimer DD
    Br J Clin Pharmacol; 1989 Jan; 27(1):75-81. PubMed ID: 2706190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal bioavailability of insulin powder formulations: effect of permeation enhancer-to-protein ratio.
    Lee WA; Narog BA; Patapoff TW; Wang YJ
    J Pharm Sci; 1991 Aug; 80(8):725-9. PubMed ID: 1791529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of phenothiazines to enhance the rectal absorption of water-soluble compounds.
    Fix JA; Leppert PS; Porter PA; Alexander J
    J Pharm Pharmacol; 1984 Apr; 36(4):286-8. PubMed ID: 6144788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep.
    Longenecker JP; Moses AC; Flier JS; Silver RD; Carey MC; Dubovi EJ
    J Pharm Sci; 1987 May; 76(5):351-5. PubMed ID: 3309255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption enhancement of rectally infused cefoxitin sodium by medium-chain fatty acids in conscious rats: concentration-effect relationship.
    van Hoogdalem EJ; Hardens MA; de Boer AG; Breimer DD
    Pharm Res; 1988 Jul; 5(7):453-6. PubMed ID: 3247317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of bile acids and fusidate derivative as nasal absorption enhancers using an electrophysiological technique.
    Hosoya K; Kubo H; Natsume H; Sugibayashi K; Morimoto Y
    Biol Pharm Bull; 1999 Oct; 22(10):1089-93. PubMed ID: 10549861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption enhancement of rectally infused cefoxitin by medium chain monoglycerides in conscious rats.
    Watanabe Y; van Hoogdalem EJ; de Boer AG; Breimer DD
    J Pharm Sci; 1988 Oct; 77(10):847-9. PubMed ID: 3236226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption-promoting adjuvants: animal studies on their effects on rectal drug absorption.
    Caldwell L; Nishihata T; Fix J; Selk S; Cargill R; Gardner CR; Higuchi T
    Methods Find Exp Clin Pharmacol; 1984 Sep; 6(9):503-7. PubMed ID: 6392793
    [No Abstract]   [Full Text] [Related]  

  • 17. Possible mechanism behind the adjuvant action of phosphate derivatives on rectal absorption of cefoxitin in rats and dogs.
    Nishihata T; Lee CS; Nghiem BT; Higuchi T
    J Pharm Sci; 1984 Nov; 73(11):1523-5. PubMed ID: 6520749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption enhancers as tools to determine the route of nasal absorption of peptides.
    Donnelly A; Kellaway IW; Taylor G; Gibson M
    J Drug Target; 1998; 5(2):121-7. PubMed ID: 9588868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of absorption enhancers on human nasal tissue ciliary movement in vitro.
    Hermens WA; Hooymans PM; Verhoef JC; Merkus FW
    Pharm Res; 1990 Feb; 7(2):144-6. PubMed ID: 2408030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer.
    Lee WA; Ennis RD; Longenecker JP; Bengtsson P
    Pharm Res; 1994 May; 11(5):747-50. PubMed ID: 8058647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.